There is one clinical trial.
Evaluating the efficacy of Tocilizumab in hospitalized patients in the inflammatory phase of COVID-19. Randomization 2:1 (TCZ:standard of care).
Description: (assessed using 7-category ordinal scale) 7 death 6 in ICU with ECMO/ mechanical ventilation 5 in ICU, no ECMO/ mechanical ventilation 4 in hospital, not ICU, needs supplementary oxygen 3 in hospital, not ICU, no supplementary oxygen 2 not in hospital, but not back to normal 1 not in hospital, back to normalMeasure: Clinical status at day 28 Time: day 28
Description: defined as a National Early Warning Score 2 (NEWS2) of>/=2 maintained for 24 hoursMeasure: Time to clinical improvement Time: 28 days
Description: relative on a 7-category ordinalscale of clinical statusMeasure: Time to decline of at least 2 categories Time: 28 days
Description: (mode and duration of respiratory support) Hospital day when respiratory support needed with non-invasive ventilation - and duration. Hospital day when respiratory support needed by invasive mechanical ventilation -and duration.Measure: Incidence of mechanical and/or non-invasive ventilation Time: 28 days
Description: days not in ventilatorMeasure: Number of ventilator-free days to day 28 Time: 28 days
Description: days without organ failureMeasure: Organ failure free days to day 28 Time: 28 days
Description: ICU admission dayMeasure: Incidence of ICU stay Time: 28 days
Description: days on ICUMeasure: Duration of ICU stay Time: 28 days
Description: time to death, mechanical ventilation, or ICU admission (whichever occurs first)Measure: Time to clinical failure Time: 28 days
Description: during ICU stay SAPS II = simplified acute physiology score II min 0 (best), max 163 (worst)Measure: SAPS II Time: 28 days
Description: during ICU stay CCI = Charlson Comorbidity Index min 0 (best), max 37 (worst)Measure: CCI Time: 28 days
Description: during ICU stay APACHE II = acute physiology and chronic health evaluation II min 0 (best), max 71 (worst)Measure: APACHE II Time: 28 days
Description: during ICU stay SOFA 6 = sequential organ failure assessment min 0 (best), max 24 (worst)Measure: SOFA 6 Time: 28 days
Description: during and end of period of 28 daysMeasure: Mortality rate Time: 28 days
Description: as evidenced by normal body temperature and respiratory rate and stable oxygen saturation on ambient air or =2 l supplemental oxygenMeasure: Time to hospital discharge or "ready for discharge" Time: 28 days
Description: days on suppl oxygenMeasure: Duration of supplemental oxygen Time: 28 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports